AREC — Arecor Therapeutics Share News
0.000.00%
Last trade - 00:00- £37.37m
- £34.28m
- £1.71m
Arecor Therapeutics - Grant of Options and PDMR Dealing
Arecor Therapeutics - Final results for 2024
Arecor Therapeutics - Notice of Results
Brief: Arecor Therapeutics Enters Collaboration With Pharmaceutical Partner
Arecor Therapeutics - Collaboration with global pharmaceutical partner
Brief: Arecor Therapeutics Partners With Biopharma Firm For Novel Peptide Therapy
Brief: Arecor Therapeutics Says Non-Clinical PK Data For Oral GLP-1 On Track To Be Delivered In H1'25
Brief: Arecor Therapeutics FY Rev GBP 5.1 Mln
Arecor Therapeutics - Arecor Full Year 2024 Trading Update
Brief: Arecor Therapeutics Announces Orderly Cessation Of Tetris Pharma Operations in 2025
Brief: Arecor Therapeutics Signs Exclusive Licensing Agreement For AT351
Arecor Therapeutics - Arecor Signs Exclusive Licensing Agreement
Arecor Therapeutics - Grant of Options and PDMR Dealing
Brief: Arecor Therapeutics Appoints David Ellam As Interim CFO
Arecor Therapeutics - Arecor Appoints Interim Chief Financial Officer
RCS - Arecor Therapeutics - Arecor to present on Investor Meet Company
Brief: Arecor Therapeutics Sees To Achieve 2024 Consensus Analyst Revenue Market Views
Arecor Therapeutics - Interim Results for six months ended 30 June 2024
Arecor Therapeutics - Notice of Results